

Farzana D Pashankar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8561605/publications.pdf>

Version: 2024-02-01

48
papers

970
citations

516710

16
h-index

454955

30
g-index

50
all docs

50
docs citations

50
times ranked

1321
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt. <i>International Journal of Hematology</i> , 2022, 115, 399-405.	1.6	1
2	A microfluidic-informatics assay for quantitative physical occlusion measurement in sickle cell disease. <i>Lab on A Chip</i> , 2022, 22, 1126-1136.	6.0	1
3	Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. <i>European Journal of Cancer</i> , 2022, 173, 59-70.	2.8	6
4	Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2021, 34, 383-386.	0.7	6
5	Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e184-e186.	0.6	0
6	P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS390-TPS390.	1.6	0
7	Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28970.	1.5	9
8	Emotion regulation, pain interference and affective symptoms in children and adolescents with sickle cell disease. <i>Journal of Affective Disorders</i> , 2021, 282, 829-835.	4.1	5
9	Re: "Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis". <i>European Journal of Cancer</i> , 2021, 152, 255-256.	2.8	2
10	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 2463-2473.	1.6	38
11	Patterns of medication use at end of life by pediatric inpatients with cancer. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28837.	1.5	1
12	Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e630-e633.	0.6	8
13	Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e659-e661.	0.6	2
14	Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. <i>Nature Communications</i> , 2020, 11, 3549.	12.8	103
15	Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. <i>European Journal of Cancer</i> , 2020, 130, 265-266.	2.8	0
16	P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS425-TPS425.	1.6	0
17	Î±-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. <i>Cancer</i> , 2019, 125, 3649-3656.	4.1	10
18	Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3369-3376.	1.6	40

#	ARTICLE	IF	CITATIONS
19	<p>Hemoglobin level and macular thinning in sickle cell disease</p>. Clinical Ophthalmology, 2019, Volume 13, 627-632.	1.8	6
20	Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2019, 37, 396-402.	1.6	11
21	Improving Care for Sickle Cell Pain Crisis Using a Multidisciplinary Approach. Pediatrics, 2019, 143, .	2.1	22
22	Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.. Journal of Clinical Oncology, 2019, 37, 10022-10022.	1.6	1
23	Carcinomas in the children and young adults: A report form Children's Oncology Group APEC14B1 study.. Journal of Clinical Oncology, 2019, 37, e21505-e21505.	1.6	2
24	Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.. Journal of Clinical Oncology, 2019, 37, 10036-10036.	1.6	0
25	Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatric Blood and Cancer, 2018, 65, e27111.	1.5	11
26	Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal of Cancer, 2018, 98, 30-37.	2.8	38
27	Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?. Gynecologic Oncology, 2018, 150, 253-260.	1.4	21
28	P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. Journal of Clinical Oncology, 2018, 36, TPS574-TPS574.	1.6	0
29	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. Journal of Clinical Oncology, 2018, 36, TPS4596-TPS4596.	1.6	0
30	Immature Ovarian Teratoma: When to Give Adjuvant Therapy?. Journal of Pediatric Hematology/Oncology, 2017, 39, 487-489.	0.6	14
31	Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2017, 35, 1203-1210.	1.6	20
32	Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the <sc>M</sc>alignant <sc>G</sc>erm <sc>C</sc>ell <sc>T</sc>umor <sc>I</sc>nternational <sc>C</sc>ollaborative. Cancer, 2016, 122, 230-237.	4.1	91
33	Paediatric extracranial germ-cell tumours. Lancet Oncology, The, 2016, 17, e149-e162.	10.7	60
34	Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal of Clinical Oncology, 2015, 33, 195-201.	1.6	111
35	The Role of Registries and Tumor Banking in Rare Pediatric Tumors. Current Pediatrics Reports, 2015, 3, 128-136.	4.0	1
36	Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2015, 37, 242-243.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3018-3028.	1.6	63
38	Massive splenic infarction in an adolescent with hemoglobin Sâ€HPFH. <i>Pediatric Blood and Cancer</i> , 2013, 60, E49-51.	1.5	7
39	Development of a Therapeutic Approach to Rare Cancers in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, S37-S38.	0.6	4
40	Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2012, 58, 937-940.	1.5	20
41	Acute Constipation in Children Receiving Chemotherapy for Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e300-e303.	0.6	19
42	Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease. <i>Blood</i> , 2011, 118, 4841-4841.	1.4	15
43	Genetics of HbF and HbF Response to Hydroxyurea In Pediatric Sickle Cell Disease: A Multi-Site Pilot Analysis of Candidate SNP Variants. <i>Blood</i> , 2010, 116, 2641-2641.	1.4	1
44	Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease. <i>Blood</i> , 2010, 116, 255-255.	1.4	1
45	Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. <i>British Journal of Haematology</i> , 2009, 144, 736-741.	2.5	58
46	Sickle cell disease complicated by postâ€streptococcal glomerulonephritis, cerebral hemorrhage and reversible posterior leucoencephalopathy syndrome. <i>Pediatric Blood and Cancer</i> , 2008, 50, 864-866.	1.5	11
47	Prevalence and Risk Factors of Elevated Pulmonary Artery Pressures in Children With Sickle Cell Disease. <i>Pediatrics</i> , 2008, 121, 777-782.	2.1	96
48	Intact T cell responses in ataxia telangiectasia. <i>Clinical Immunology</i> , 2006, 120, 156-162.	3.2	20